Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SYNB2081
- Development stage
- Discontinued
- Lead developer
- Synlogic
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
SYNB2081 is an orally administered **Synthetic Biotic** medicine developed by **Synlogic** in collaboration with **Ginkgo Bioworks** for the treatment of **gout**. It consists of an engineered strain of the probiotic bacterium *Escherichia coli* Nissle 1917, designed to degrade uric acid (urate) within the gastrointestinal tract. By acting as a metabolic sink to consume urate in the gut, SYNB2081 aims to lower systemic uric acid levels, thereby preventing the formation of painful urate crystals in the joints. The program leveraged Ginkgo's synthetic biology platform and foundry services for microbial engineering. However, in February 2023, Synlogic announced the discontinuation of the SYNB2081 program as part of a strategic reprioritization to focus resources on its lead programs in phenylketonuria (PKU) and homocystinuria (HCU).
- Other names
- SYNB2081SYNB-2081SYNB 2081
Beyond the preview
Go deeper on SYNB2081.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SYNB2081.